TERT and glioblastoma: Despite rGBM frequently hosting TERT promoter mutations supporting tumor cells’ immortalization, the pharmacological inhibition of TERT abnormal transcription has not yet been considered for extensive investigation, let alone sparse preclinical studies on GBM models [64,65,66].